or
forgot password
  • cancer clinical trials in manchester, CT

  • Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Adenocarcinoma of the Colon, Stage III Colon Cancer
    Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders.
    Bruce Stein, MD
    Manchester, Connecticut 06040
    Hepatitis C Virus, Advanced Fibrosis, Cirrhosis
    Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
    Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Breast Cancer, Cancer Survivor, Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment, Sexuality and Reproductive Issues, Spiritual Concerns
    Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIB Breast Cancer
    Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
    Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
    Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
    Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer
    Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Breast Cancer, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Musculoskeletal Complications, Pain, Prostate Cancer, Urinary Complications
    Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Prostate Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Stage IV Prostate Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
    Connect® MM- The Multiple Myeloma Disease Registry
    Medical Oncology and Blood Disorders, LLP
    Manchester, Connecticut 06040
    Multiple Myeloma
    Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
    Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Light Chain Deposition Disease, Smoldering Multiple Myeloma
    Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
    Medical Oncology and Blood Disorders, LLP
    Manchester, Connecticut 06040
    Chronic Myeloid Leukemia
    Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
    Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer
    Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Breast Cancer
    Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
    Davis, Posteraro, & Wasser, MDs, LLP
    Manchester, Connecticut 06040
    Pancreatic Cancer
    OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
    DeQuattro Community Cancer Center
    Manchester, Connecticut 06040
    Pancreatic Cancer
    Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
    Manchester Hematology/Oncology Assoc.
    Manchester, Connecticut 06040
    Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
    Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
    Davis, Posteraro and Wasser, MD's, LLP
    Manchester, Connecticut 06040
    Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
    Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
    DeQuattro Community Cancer Center
    Manchester, Connecticut 06040
    Prostate Cancer, Hormone Refractory Prostate Cancer
    Levocarnitine in Treating Fatigue in Cancer Patients
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
    Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Breast Cancer
    Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
    Davis, Posteraro and Wasser, MDs, LLP
    Manchester, Connecticut 06105
    Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
    Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)
    Davis, Posteraro, and Wasser, MDs, LLP
    Manchester, Connecticut 06040
    Prostate Cancer
    Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
    Davis, Posteraro and Wasser, MD's LLP
    Manchester, Connecticut 06040
    Immune Thrombocytopenic Purpura
    Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic ITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
    Davis, Posteraro and Wasser, MDs, LLP
    Manchester, Connecticut 06105
    Idiopathic Thrombocytopenic Purpura
    Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery
    Manchester Memorial Hospital
    Manchester, Connecticut 06040-4188
    Colorectal Cancer, Metastatic Cancer